Morgan Stanley
ARCT icon

Morgan Stanley’s Arcturus Therapeutics ARCT Stock Holding History

Morgan Stanley’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$655K Sell
97,406
-28,729
-23% -$226K ﹤0.01% 5429
2026
Q1 		$974K Sell
126,135
-87,257
-41% -$637K ﹤0.01% 5157
2025
Q4 		$1.31M Sell
213,392
-491,486
-70% -$5.31M ﹤0.01% 5052
2025
Q3 		$13M Buy
704,878
+101,282
+17% +$1.63M ﹤0.01% 3306
2025
Q2 		$7.85M Buy
603,596
+51,870
+9% +$613K ﹤0.01% 3674
2025
Q1 		$5.84M Buy
551,726
+13,232
+2% +$210K ﹤0.01% 3793
2024
Q4 		$9.14M Buy
538,494
+271,572
+102% +$5.11M ﹤0.01% 3479
2024
Q3 		$6.2M Sell
266,922
-529,019
-66% -$11.3M ﹤0.01% 3806
2024
Q2 		$19.4M Sell
795,941
-72,506
-8% -$2.2M ﹤0.01% 2705
2024
Q1 		$29.3M Sell
868,447
-295,547
-25% -$10.5M ﹤0.01% 2272
2023
Q4 		$36.7M Buy
1,163,994
+590,362
+103% +$14M ﹤0.01% 2776
2023
Q3 		$14.7M Buy
573,632
+365,215
+175% +$11.3M ﹤0.01% 2766
2023
Q2 		$5.98M Buy
208,417
+90,842
+77% +$2.47M ﹤0.01% 3631
2023
Q1 		$2.82M Sell
117,575
-3,053
-3% -$54.8K ﹤0.01% 4238
2022
Q4 		$2.05M Buy
120,628
+36,042
+43% +$628K ﹤0.01% 4449
2022
Q3 		$1.25M Sell
84,586
-227,625
-73% -$3.82M ﹤0.01% 4747
2022
Q2 		$4.91M Buy
312,211
+32,241
+12% +$633K ﹤0.01% 3787
2022
Q1 		$7.55M Buy
279,970
+142,391
+103% +$3.63M ﹤0.01% 3237
2021
Q4 		$5.09M Buy
137,579
+4
+0% +$163 ﹤0.01% 3705
2021
Q3 		$6.57M Sell
137,575
-109,969
-44% -$4.93M ﹤0.01% 3392
2021
Q2 		$8.38M Buy
247,544
+159,019
+180% +$5.38M ﹤0.01% 3196
2021
Q1 		$3.66M Buy
88,525
+47,900
+118% +$2.86M ﹤0.01% 3736
2020
Q4 		$1.76M Buy
40,625
+7,269
+22% +$492K ﹤0.01% 4264
2020
Q3 		$1.43M Sell
33,356
-118,906
-78% -$5.9M ﹤0.01% 3945
2020
Q2 		$7.12M Sell
152,262
-49,977
-25% -$1.72M ﹤0.01% 2303
2020
Q1 		$2.75M Buy
202,239
+43,497
+27% +$557K ﹤0.01% 3060
2019
Q4 		$1.73M Buy
158,742
+79,712
+101% +$834K ﹤0.01% 4148
2019
Q3 		$812K Buy
79,030
+35,840
+83% +$387K ﹤0.01% 4421
2019
Q2 		$408K Sell
43,190
-26,888
-38% -$197K ﹤0.01% 4709
2019
Q1 		$479K Sell
70,078
-1,504
-2% -$7.69K ﹤0.01% 4563
2018
Q4 		$324K Buy
71,582
+23,617
+49% +$145K ﹤0.01% 5058
2018
Q3 		$424K Sell
47,965
-4,858
-9% -$40.4K ﹤0.01% 5086
2018
Q2 		$448K Buy
52,823
+13,961
+36% +$90.4K ﹤0.01% 5173
2018
Q1 		$214K Buy
38,862
+4,736
+14% +$32.7K ﹤0.01% 5438
2017
Q4 		$271K Sell
34,126
-2,430
-7% -$21.9K ﹤0.01% 5297
2017
Q3 		$259K Buy
36,556
+4,809
+15% +$36.2K ﹤0.01% 5222
2017
Q2 		$249K Sell
31,747
-35,752
-53% -$288K ﹤0.01% 5214
2017
Q1 		$539K Buy
67,499
+65,494
+3,267% +$606K ﹤0.01% 4783
2016
Q4 		$29K Sell
2,005
-765
-28% -$11.4K ﹤0.01% 5896
2016
Q3 		$48K Sell
2,770
-272
-9% -$8.79K ﹤0.01% 5609
2016
Q2 		$96K Sell
3,042
-152
-5% -$4.79K ﹤0.01% 5258
2016
Q1 		$85K Sell
3,194
-746
-19% -$25.3K ﹤0.01% 5385
2015
Q4 		$173K Sell
3,940
-2,161
-35% -$97.3K ﹤0.01% 5159
2015
Q3 		$258K Sell
6,101
-47
-0.8% -$2.47K ﹤0.01% 4971
2015
Q2 		$282K Sell
6,148
-225
-4% -$10.3K ﹤0.01% 5071
2015
Q1 		$251K Buy
6,373
+2,022
+46% +$89K ﹤0.01% 5083
2014
Q4 		$114K Sell
4,351
-12,211
-74% -$388K ﹤0.01% 5495
2014
Q3 		$1.79M Buy
16,562
+2,650
+19% +$345K ﹤0.01% 3541
2014
Q2 		$1.69M Buy
13,912
+9,343
+204% +$1.13M ﹤0.01% 3625
2014
Q1 		$580K Buy
4,569
+3,836
+523% +$569K ﹤0.01% 4444
2013
Q4 		$92K Buy
+733
New +$92.1K ﹤0.01% 5375

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley's ARCT Position: Q2 2026 in Review

Morgan Stanley reduced its Arcturus Therapeutics (ARCT) stake by 23% in Q2 2026, selling an estimated $226K and leaving 97,406 shares worth $655K. The position accounts for ﹤0.01% of the portfolio, ranked #5429.

Morgan Stanley first reported a position in ARCT in Q4 2013 and has held it in 51 quarters since. The position peaked at $36.7M in Q4 2023. 125 funds tracked by Wall St. Rank hold ARCT as of Q2 2026.

  • Morgan Stanley held 97,406 shares of Arcturus Therapeutics worth $655K as of Q2 2026.
  • Morgan Stanley sold 28,729 Arcturus Therapeutics shares in Q2 2026, an estimated $226K.
  • Arcturus Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #5429 holding.
  • Morgan Stanley first reported a position in Arcturus Therapeutics in Q4 2013 and has held it in 51 quarters since.
  • Morgan Stanley's Arcturus Therapeutics position peaked at $36.7M in Q4 2023.
  • 125 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.